Physician profile
James B Smart
NPI 1477592541
$693.15
in general payments reported to CMS, 2019-2025
19 companies · $29.57 in 2025
The $29.57 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.00 · 2020: $85.61 · 2021: $56.36 · 2022: $79.59 · 2023: $180 · 2024: $217 · 2025: $29.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401 · Education: $25.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.83 |
| Education | $25.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $118.87 | 2020-2024 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $59.94 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $59.34 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $56.98 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.24 | 2021-2024 | |
| Lilly USA, LLC | $47.50 | 2024 | Jardiance |
| Leadiant Biosciences, INC. | $45.51 | 2023 | Carnitor |
| Amgen INC. | $29.57 | 2025 | Tavneos |
| Scpharmaceuticals INC. | $29.29 | 2024 | |
| Opko Pharmaceuticals, LLC | $25.76 | 2023 | Rayaldee |
| Glaxosmithkline, LLC. | $24.65 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.30 | 2023 | Ultomiris |
| Vifor Pharma, INC. | $22.26 | 2023 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.28 | 2024 | Jardiance |
| Baxter Healthcare | $19.98 | 2023 | Renal - Pd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.86 | 2024 | |
| Dexcom, INC. | $15.24 | 2024 | Dexcom G6 Transmitter |
| Mallinckrodt Enterprises LLC | $14.43 | 2019 | |
| Novo Nordisk INC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.